Triple Negative Breast Cancer

MSD is proud to announce the newly approved indication for KEYTRUDA® in early triple-negative breast cancer (TNBC) based on the landmark KEYNOTE-522 trial.

KEYTRUDA® is indicated in:1

KEYTRUDA® (pembrolizumab), in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced or early-stage TNBC at high risk of recurrence.

aCarboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide.

Key findings from the KEYNOTE-522 trial:2

Pathological complete response: Pathological stage ypT0/Tis ypN0 at the time of definitive surgery.

Maximize your patient’s chances of success with KEYTRUDA®.

CI: Confidence interval; NACT: Neoadjuvant chemotherapy; pCR: Pathological complete response; PD-L1: Programmed death-ligand 1.

References

  1. Keytruda® Prescribing Information, MSDIN 06/23.
  2. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821.

IN-KEY-01092, 14/102023 – 14/9/2025